Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

48.52 +1.43 (+3.04%)

Streaming Delayed Price Updated: 11:47 AM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot ↗

December 22, 2021

The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022.

Via Talk Markets

10 Bargain Stocks to Buy After Falling 30% in 2021 ↗

December 20, 2021

If you’re looking for bargain stocks to buy that are down 30% or more in 2021, that’s not an easy task. Here are 10 that fit the bill.

Via InvestorPlace

Biotech Playbook 2021: No Help From Small Caps In Q4 ↗

December 14, 2021

Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but...

Via Talk Markets

Adobe Earnings Strangle Trade ↗

December 11, 2021

Adobe announces earnings this week, and we plan on using an options strategy called a

Via Talk Markets

CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments ↗

December 09, 2021

Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

Why CRISPR Therapeutics Stock Sank 12.5% in November ↗

December 05, 2021

The gene-editing specialist's share price is now down roughly 54% in 2021.

Via The Motley Fool

Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More ↗

November 30, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ:

Via Benzinga

Biotech Stocks are Due for a Rally ↗

November 22, 2021

There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums.

Via Talk Markets

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗

November 21, 2021

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Via The Motley Fool

Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗

November 20, 2021

The companies are collaborating on a potential blockbuster.

Via The Motley Fool

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Being First Is Not Enough For Crispr Therapeutics ↗

November 15, 2021

CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies.

Via InvestorPlace

Why CRISPR Therapeutics Stock Fell 18.4% in October ↗

November 04, 2021

The gene-editing specialist's stock is now down roughly 37% year to date.

Via The Motley Fool

Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗

November 04, 2021

Vertex plans to develop gene-editing therapies with Mammoth Biosciences.

Via The Motley Fool

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

October 20, 2021

The company's value isn't reflected in typical performance metrics.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗

October 19, 2021

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:

Via Benzinga

2 Gene-Editing Stocks to Have on Your Radar Right Now ↗

October 17, 2021

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Via The Motley Fool

2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗

October 16, 2021

These two novel-drug makers could be top takeover targets next year.

Via The Motley Fool

If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today ↗

October 16, 2021

The returns haven't been half bad, to say the least.

Via The Motley Fool

Crispr: A Fallen Angel In Gene Editing ↗

October 16, 2021

As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it...

Via Talk Markets

Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗

October 15, 2021

It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields.

Via Investor's Business Daily

BZ Chart Of The Day: Is Crisper Therapeutics About To Rally? ↗

October 15, 2021

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form...

Via Benzinga

The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗

October 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc...

Via Benzinga

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today ↗

October 13, 2021

Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial.

Via InvestorPlace

40 Stocks Moving In Wednesday's Mid-Day Session ↗

October 13, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...

Via Benzinga

Why CRISPR Therapeutics Stock Is Sinking Today ↗

October 13, 2021

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

Via The Motley Fool

Why CRISPR Therapeutics Stock Is Tumbling Today ↗

October 13, 2021

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

< Previous 1 2

...

29 30 31 32 33 34 35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.